IGF-1 LR3: Research Overview

IGF-1 LR3 (Long Arg3 Insulin-Like Growth Factor-1) is a synthetic peptide analog of human IGF-1, engineered in the early 1990s to solve a fundamental pharmacokinetic problem: the near-complete sequestration of exogenous IGF-1 by IGF-binding proteins in serum. The analog has since become a standard research reagent in growth factor biology, used across skeletal muscle physiology, developmental biology, neuroprotection, and oncology research. This hub page covers what IGF-1 LR3 is, where it comes from, how it fits into the GH-IGF-1 axis, and the landscape of research programs that have used it.

Compound Identity

IGF-1 LR3 is not a natural hormone. It does not occur in any tissue or biofluid. It was constructed by prepending a synthetic 13-residue sequence to the B-domain of human IGF-1 and substituting the glutamic acid at position 3 of native IGF-1 with arginine. The compound retains full high-affinity binding to IGF-1R while losing almost all affinity for the six circulating IGF-binding proteins (PMID 11735239, PMID 15817840).

Historical and Scientific Context

The GH-IGF-1 Axis

Insulin-like growth factor 1 was first described as “sulfation factor” in the 1950s, later renamed somatomedin C before receiving its current designation. It is produced primarily by the liver under growth hormone (GH) stimulation and is also synthesized locally in most tissues. IGF-1 mediates the majority of GH’s anabolic and growth-promoting effects during postnatal development.

In circulation, more than 99% of IGF-1 is bound to six IGF-binding proteins (IGFBP-1 through IGFBP-6). The predominant form is a ternary complex with IGFBP-3 and an acid-labile subunit (ALS), which extends IGF-1’s plasma half-life from minutes (for free IGF-1) to approximately 12-15 hours. This sequestration system is physiologically important: it buffers free IGF-1 levels, acts as a reservoir, and enables tissue-specific IGF-1 bioavailability through IGFBP proteolysis and local gradients (PMID 23686362).

flowchart LR
    A["Growth Hormone\n(pituitary)"] --> B["Liver & tissues\nIGF-1 secretion"]
    B --> C{"IGFBP binding\n>99% sequestered"}
    C -->|"IGFBP-3 + ALS\nternary complex"| D["Reservoir pool\n12-15 hr half-life"]
    C -->|"Free fraction (<1%)"| E["IGF-1R\nat target tissues"]
    E --> F["PI3K/Akt/mTOR\nanabolic cascade"]
    E --> G["MAPK/ERK\nproliferative cascade"]

    H["IGF-1 LR3\n(synthetic analog)"] -->|"IGFBP affinity ~1000x lower"| I["Remains predominantly free"]
    I --> E

    style A fill:#5b8dd9,color:#fff
    style H fill:#e07b39,color:#fff
    style I fill:#e07b39,color:#fff
    style E fill:#7b68ee,color:#fff
    style F fill:#2e8b57,color:#fff
    style G fill:#2e8b57,color:#fff

Development of IGFBP-Resistant Analogs

The recognition that exogenous IGF-1 added to serum-containing cell cultures is rapidly sequestered by secreted IGFBPs motivated development of IGFBP-resistant analogs in the late 1980s and early 1990s. Two principal approaches emerged:

1. des(1-3)IGF-1: deletion of the first three N-terminal residues of native IGF-1, which disrupts key IGFBP contact points.
2. Long R3 IGF-1 (IGF-1 LR3): addition of a 13-residue N-terminal extension and substitution of Glu3 with Arg, achieving similar IGFBP resistance with a defined sequence.

IGF-1 LR3 was developed and characterized by researchers at GroPep (Australia) in the early 1990s. Preclinical pharmacology work confirmed that the analog has IGF-1R binding affinity comparable to native IGF-1, but affinities for all six IGFBPs reduced by approximately three orders of magnitude (PMID 11735239). Because the receptor-binding residues on the B and A domains are preserved and unobstructed, the downstream signal transduction cascade initiated by IGF-1 LR3 is identical to that of native IGF-1.

IGF-1 LR3 is now commercially supplied by multiple reagent manufacturers as a recombinant protein produced in E. coli or other expression systems, and is used as a serum-free medium supplement in bioreactor cell culture as well as a pharmacological tool in animal studies.

Receptor Biology Summary

IGF-1 LR3 acts exclusively through engagement of the IGF-1 receptor (IGF-1R), a heterotetrameric receptor tyrosine kinase structurally homologous to the insulin receptor. Ligand binding induces receptor trans-autophosphorylation, which activates two principal downstream signaling branches:

• PI3K/Akt/mTOR axis: drives protein synthesis (via mTORC1, S6K1, 4E-BP1), suppresses protein degradation (via FoxO1/FoxO3a phosphorylation and consequent downregulation of MuRF1 and Atrogin-1), and inhibits apoptosis.
• MAPK/ERK axis: drives cell proliferation, gene expression, and differentiation via Ras-Raf-MEK-ERK signaling.

At the high concentrations used in some in vitro studies, IGF-1 LR3 can also engage the insulin receptor (IR) and hybrid IGF-1R/IR complexes, but IGF-1R remains the primary signaling receptor under standard experimental conditions (PMID 34074726).

The receptor pharmacology and downstream signaling cascade are summarized in the sections below.

Primary Research Programs

Skeletal Muscle Biology

The largest body of preclinical research on IGF-1 LR3 concerns skeletal muscle. The PI3K/Akt/mTOR axis downstream of IGF-1R is the primary intracellular regulator of muscle protein synthesis, and the Akt-FoxO pathway suppresses the ubiquitin-proteasome machinery responsible for muscle protein degradation.

Key published findings include:

• Myoblast and myotube cultures: LR3-IGF-1 demonstrates 2- to 10-fold greater potency than equimolar native IGF-1 in promoting myoblast proliferation and myotube protein synthesis in serum-containing media, attributable entirely to IGFBP evasion rather than altered receptor binding (PMID 15817840).
• Satellite cell activation: IGF-1 LR3 has been used to stimulate satellite cell proliferation in primary bovine and porcine muscle cell cultures, clarifying the role of autocrine/paracrine IGF-1 signaling in muscle regeneration (PMID 24906928, PMID 17049199).
• Cancer cachexia models: IGF-1 LR3 infusion was used as a positive control in rodent models of cancer-associated muscle wasting (cachexia) to benchmark anabolic signaling activation. Activin-like kinase 4/5 inhibition was compared to LR3-IGF-1 treatment in this context (PMID 31285507).
• Atrophy prevention: the IGF-1/Akt/FoxO axis is central to the physiology of disuse atrophy and sarcopenia. LR3-IGF-1 is used in ex vivo and in vivo models to probe the rescue capacity of IGF-1R activation in atrophying muscle (PMID 23686362, PMID 32858949).

The muscle-biology literature using IGF-1 LR3 is predominantly preclinical. No completed randomized controlled trials have evaluated IGF-1 LR3 specifically in human skeletal muscle disorders.

Fetal and Neonatal Development

A substantial body of ovine (sheep) research has used IGF-1 LR3 as an infusion agent to probe fetal growth regulation:

• Organ-specific growth: Continuous IGF-1 LR3 infusion into late-gestation fetal sheep increases fetal weight and organ-specific growth (liver, spleen, kidney), demonstrating that IGF-1 is a direct fetal growth regulator independent of nutrient transfer (PMID 33427051, PMID 36091374).
• Pancreatic beta-cell function: One-week IGF-1 LR3 infusion in fetal sheep reduced glucose-stimulated insulin secretion, suggesting feedback suppression of beta-cell function via IGF-1R signaling; acute infusion recapitulated this effect (PMID 33938236, PMID 37114757).
• Rumen epithelium: IGF-1 LR3 acutely stimulates sodium transport across ovine rumen epithelium via IGF-1R, identifying a role for the IGF-1 axis in gastrointestinal ion transport (PMID 22227200).

This research program uses IGF-1 LR3 primarily because native IGF-1 is rapidly neutralized by fetal plasma IGFBPs, making dose-response characterization difficult; the analog allows controlled receptor stimulation.

Mammary Gland Biology and Lactation

IGF-1 LR3 has been used extensively in mammary cell biology to understand IGF-1’s role in lactogenesis and milk production:

• Mouse GH combined with Long-R3-IGF-I extended lactation performance in mice, with downstream changes in mammary gland signaling including Akt and STAT5 activation and altered expression of milk-protein genes (PMID 18577570).
• In bovine mammary cell lines and primary cultures, IGF-1 LR3 is a standard mitogen used to characterize proliferative signaling, receptor expression, and the interaction between IGF-1R and other receptor systems such as EGFR (PMID 24906928).

Neuroprotection and Neurodegeneration

Interest in IGF-1 LR3 in CNS research has grown from the established roles of IGF-1 in neuronal survival, synaptic plasticity, and neurogenesis:

• Alzheimer’s disease model: Intranasal Long R3 IGF-1 treatment in 5XFAD mice (a transgenic amyloid-overexpression model) promoted amyloid plaque remodeling in cerebral cortex. Cognitive function was not preserved in this study, indicating dissociation between plaque burden and behavioral outcomes under the tested conditions (PMID 39610283).
• Broader IGF-1R neuroprotection research, not specific to LR3, has implicated the PI3K/Akt/mTOR and MAPK cascades in neuronal survival, and IGF-1 LR3 has been used as a positive control in many cell culture neuroprotection assays due to its serum stability.

Cardiovascular Research

IGF-1R is expressed in cardiomyocytes, cardiac fibroblasts, and vascular smooth muscle cells. IGF-1 LR3 has been applied in cardiovascular biology to probe:

• Cardiomyocyte proliferation: ERK1/2 and PI3K/Akt pathways mediate IGF-1-driven fetal sheep cardiomyocyte proliferation, documented using IGF-1 LR3 as the receptor stimulus (PMID 12947030).
• Atherosclerosis: Native IGF-1 (not LR3 specifically) has plaque-stabilizing effects in atherosclerosis by shifting vascular smooth muscle cell phenotype; this research contextualizes the cardiovascular relevance of IGF-1R activation (PMID 21281823).
• IGF-1 cardiac transport: Studies using radiolabeled IGF-1 and IGFBP-3 clarify the kinetics of IGF-1 delivery to cardiac tissue, informing interpretation of LR3 analog experiments in this tissue (PMID 12485812).

Cancer Biology

IGF-1R is overexpressed or hyperactivated in multiple tumor types, and its downstream PI3K/Akt and MAPK pathways are among the most commonly altered in cancer. IGF-1 LR3 has been employed in cancer research contexts:

• As a positive control stimulus for IGF-1R-mediated PI3K/Akt signaling in tumor cell lines.
• In receptor internalization and trafficking studies, where IGFBP resistance allows sustained receptor engagement.
• In drug target validation: NKX3.1 activates IGFBP-3 expression to mediate IGF-1-dependent growth suppression in prostate cancer models (PMID 19258508); IGF-1 LR3 is used in such studies to distinguish IGFBP-dependent from receptor-dependent effects.
• In conjugate development: an IGF-1-methotrexate covalent conjugate was designed to exploit IGF-1R overexpression for tumor-targeted drug delivery, with LR3-type modifications informing the design (PMID 19446281).

IGF-1R-targeted therapies (monoclonal antibodies and small-molecule kinase inhibitors) have been evaluated in clinical oncology trials, but IGF-1 LR3 itself is not used as a therapeutic in these programs.

Research Tool Applications

Beyond pharmacological models, IGF-1 LR3 serves as a research reagent in several practical contexts:

• Serum-free cell culture: IGF-1 LR3 is a standard component of defined serum-free media formulations, particularly for Chinese hamster ovary (CHO) cell bioreactors producing recombinant proteins. Its IGFBP resistance makes it more potent per mole than native IGF-1 in maintaining cell viability and productivity without serum. Commercial recombinant IGF-1 LR3 from E. coli is widely available from reagent suppliers.
• Anti-doping context: Long R3 IGF-1 appears on the World Anti-Doping Agency (WADA) prohibited list under the category of peptide hormones, growth factors, and related substances. Detection methods based on mass spectrometry have been developed to identify the compound in urine and blood matrices. A 2010 case report documented detection of His-tagged Long-R3-IGF-I in a black-market product (PMID 20675162).
• Recombinant production research: Methods for expressing IGF-1 and LR3-IGF-1 fused to carrier proteins in Pichia pastoris have been developed to facilitate large-scale production of the analog for research use (PMID 37261455).

Clinical and Regulatory Landscape

No Approved Indication for IGF-1 LR3

IGF-1 LR3 is not approved by the FDA, EMA, or any other major regulatory agency. It has no NDA, BLA, or equivalent marketing authorization.

The closest approved compound is mecasermin (Increlex, Ipsen), which is recombinant human IGF-1 (rhIGF-1) of identical sequence to endogenous IGF-1. The FDA approved mecasermin under NDA 021839 for the long-term treatment of growth failure in pediatric patients with severe primary IGF-1 deficiency. Mecasermin rinfabate (Iplex, Insmed) was a 1:1 complex of rhIGF-1 and rhIGFBP-3, approved in 2005 but subsequently withdrawn.

Historical clinical trial programs with native recombinant IGF-1 (not LR3) include:

• ALS (amyotrophic lateral sclerosis): rhIGF-1 was evaluated in two phase III trials in the 1990s with mixed results.
• HIV-associated wasting and lipodystrophy: several trials evaluated rhIGF-1.
• Myotonic dystrophy, osteoporosis, and type 2 diabetes: smaller rhIGF-1 programs.

None of these programs used IGF-1 LR3 as the clinical compound. The IGFBP-resistance of the analog raises distinct safety considerations not present with native IGF-1, and no human safety or PK data for IGF-1 LR3 have been published.

ClinicalTrials.gov Status

A search of ClinicalTrials.gov (accessed April 2026) for “IGF-1 LR3” returns no registered studies. Trials registered under broader IGF-1 or muscle wasting terms use endogenous IGF-1 measurement as a biomarker or use rhIGF-1 as the intervention, not IGF-1 LR3 specifically.

Research Programs at a Glance

flowchart TD
    A["IGF-1 LR3\n(Research Compound)"] --> B["Skeletal Muscle"]
    A --> C["Fetal Development\n(Ovine Models)"]
    A --> D["Mammary Biology"]
    A --> E["Neuroprotection"]
    A --> F["Cardiovascular"]
    A --> G["Cancer Biology"]
    A --> H["Biotech / Cell Culture"]

    B --> B1["Myoblast proliferation\nMyotube hypertrophy\nSatellite cell activation\nAtrophy prevention"]
    C --> C1["Organ growth (liver, kidney)\nBeta-cell function\nGastrointestinal transport"]
    D --> D1["Lactation performance\nMammary signaling"]
    E --> E1["Amyloid plaque remodeling\nNeuronal survival assays"]
    F --> F1["Cardiomyocyte proliferation\nVascular SMC biology"]
    G --> G1["IGF-1R pathway validation\nDrug-receptor targeting"]
    H --> H1["Serum-free media supplement\nCHO bioreactor culture"]

    style A fill:#4a90d9,color:#fff
    style B fill:#5a9a6a,color:#fff
    style C fill:#5a9a6a,color:#fff
    style D fill:#5a9a6a,color:#fff
    style E fill:#5a9a6a,color:#fff
    style F fill:#5a9a6a,color:#fff
    style G fill:#5a9a6a,color:#fff
    style H fill:#5a9a6a,color:#fff

Compound Section Pages

This research hub connects to the other IGF-1 LR3 compound-section pages:

• Mechanism of Action - IGF-1R binding, IGFBP evasion, PI3K/Akt/mTOR and MAPK/ERK cascade detail
• Evidence (coming soon) - Systematic review of preclinical and available human evidence
• Safety (coming soon) - Preclinical safety profile and theoretical risk considerations
• Pharmacokinetics (coming soon) - Absorption, distribution, half-life, and clearance data
• Dose-Response (coming soon) - Concentration-effect relationships from in vitro and in vivo studies

Related Pathways

• IGF-1 signaling axis - GH-IGF-1-IGFBP system and downstream signaling
• PI3K/Akt Pathway - Full PI3K-Akt signaling network
• mTOR Signaling - mTORC1 and mTORC2 biology
• Growth Hormone Receptor - GH signaling upstream of IGF-1

Related Compounds

• CJC-1295 - GHRH analog that elevates endogenous GH and secondarily IGF-1
• Sermorelin - GHRH(1-29) analog; upstream GH-axis stimulant
• Tesamorelin - FDA-approved GHRH analog (HIV lipodystrophy); affects IGF-1 axis

Key Primary Literature

This page describes published research on IGF-1 LR3 for scientific and educational purposes. No dosing recommendations, sourcing guidance, health claims, or medical advice are intended or implied. IGF-1 LR3 is not approved for human therapeutic use.

See also

Pathway context:

• IGF-1 / JAK2-STAT5 Signaling Axis

Head-to-head comparisons:

• IGF-1 LR3 vs CJC-1295
• IGF-1 LR3 vs Sermorelin